Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is why I read message boards. For posts like these. 1 in 1000 it seems these days. Thank you.
I agree with you. Here's the bottom line imo - these BOM results were good and a hair away from very good imo. You are correct on the placebo being more around 70-80% making BOM 50-60% better.
We also know the UC results were extremely promising and again, possibly the formulation could make this an unbelievable drug.
THANK GOD!!! BPs interest in promising drugs has zero to do with stock message boards ;). And also THANK GOD, BPs offers on collaborations have zero to do with share price :)
IPIX is going to roll! IMO. Don't forget, Kevetrin and Prurisol data on its way
You are correct. My apologies. This kind of stuff racks my brain. I can't wait for the biotech showcase to listen to Dr B explain the data in my terms.
60-36.8 = 23.2
23.2/60 = 38.7%
That is the difference.
Those were high placebo rates - historically.
I took the data that way. I'm not sure what the confusion is. We administered B and Placebo. The results for topline was the incidence of SOM for both arms.
Meaning subtract from a 100 and you get the percentage of prevention.
Great Numbers! Thx. The great part of this......data was good and we are on full speed ahead to move this to phase 3. I am betting we will ink a deal after secondary measures are released. It could make BOM data really really good!
IV administered as well....not friendly.
Yes. I should have. Thanks
It was taken down because cox jumped on here and started complaining about privacy laws and his writings are for paid members. Sorry I am not a subscriber.
Agree. IMO. Cox trader effect, the kid that posts charts and his short crew and the original short group took this down. There is zero reason to go down on positive phase 2 data for a company that is already 3-5 dollars under valued.
We will have our day. IMO. And it will not be years away.
IMO. Why else do you meet with congress to discuss B-OM! IMO you discuss health care costs and understand treatment/incident rates.
This is an untapped market and a market that is set to grow in a big way! (Much to do with hpv)
I don't have facts and I was not included in the meeting but i can give a good guess.
Thanks. I have a better understanding with an example like that.
Just getting back to civilization and tried to read through many of the posts of the regulars that I know have good understanding of science but was curious on the numbers presented yesterday. To me, they were not as good as I wanted to see, but my hopes were to stick with interim data numbers and I think BK said...that was just not reasonable weeks ago.
But the data is somewhat confusing and I was wondering if anyone could add to my interpretation or correct me:
61 patients were enrolled.
46 patients met the cumulative radiation dose criteria of at least 55 Gy—the minimum treatment threshold for inclusion in the efficacy population
39 of these patients met more strict criteria for inclusion in the “per protocol” study population.
Is there somewhere or will there be somewhere that states what the 'more strict criteria for inclusion' is? I'd like to know why those 7 patients were excluded.
In addition, what happened to the other 15 patients? 61-46=15
Will we ever find out why they were not included? What happens if they were all Placebo and had such bad SOM they dropped out and could not take it? The numbers for Placebo would be much higher in that case?
Or what happens if some of those patients taking B-OM never got SOM and just had to stop treatment because the cancer spread to different areas and they had to move to a different location for treatment or if the patient died? I am just saying with these low numbers some details could really help IPIX.
Overall, the numbers are not bad, but they are not overwhelming unbelievable. I think they are very good and could be possibly REALLY REALLY GOOD if we knew more about the other 15 patients. That is about 25% of the trial population and they are not accounted for.
Since there is no preventative drugs I think this is a grand slam with numbers like 63.2% PREVENTION rates. I mean if I had HN cancer I would absolutely take this if my odds were over 60% less likely to get SOM especially if I only have to swish and spit.!!!
Modified Intent to Treat
(mITT) Population (n=46)
INCIDENCE OF SOM
Brilacidin: 9 of 21 patients (42.9 %)
Placebo: 15 of 25 patients (60.0%)
Per Protocol
(PP) Population (n=39)
INCIDENCE OF SOM
Brilacidin: 7 of 19 patients (36.8%)
Placebo: 12 of 20 patients (60.0%)
Overall reduction in observed severe Oral Mucositis (WHO Grade ≥ 3) in the Brilacidin-OM treatment group from that seen in the control group ([incidence control - incidence active]/incidence control) was: 28.5% (mITT population) and 38.7% (PP population).
Here are the secondary endpoints that we may see data on soon:
Secondary Outcome Measures:
Duration of severe oral mucositis (WHO Grade ≥3) [initial instance duration] [ Time Frame: 11 weeks ]
Duration of severe oral mucositis (WHO Grade ≥3), from initial WHO Grade ≥3 during radiation therapy to the first WHO Grade 2 or lower
Duration of severe oral mucositis (WHO Grade ≥3) [overall duration] [ Time Frame: 11 weeks ]
Duration of severe oral mucositis (WHO Grade ≥3), from initial WHO Grade ≥3 during radiation therapy to the last WHO Grade ≥3
Incidence of severe oral mucositis (WHO Grade ≥3) by cumulative radiation dose [ Time Frame: 7 weeks ]
Incidence of severe oral mucositis (WHO Grade ≥3) at cumulative fractions of radiation therapy
Time to onset of severe oral mucositis (WHO Grade ≥3) [ Time Frame: 7 weeks ]
Time to onset (in days, and in cumulative radiation dose) of severe oral mucositis (WHO Grade ≥3)
Exploratory: Total number of days of severe oral mucositis (WHO Grade ≥3) [ Time Frame: 11 weeks ]
Total number of days (per subject) of severe oral mucositis (WHO Grade ≥3)
Exploratory: Incidence of ulcerative oral mucositis (WHO Grade ≥2) by cumulative radiation dose [ Time Frame: 7 weeks ]
Incidence of ulcerative oral mucositis (WHO Grade ≥2) by cumulative fractions of radiation therapy
Exploratory: Time to onset of ulcerative oral mucositis (WHO Grade ≥2) [ Time Frame: 7 weeks ]
Time to onset (in days, and in cumulative radiation dose) of ulcerative oral mucositis (WHO Grade ≥2)
Exploratory: Duration of ulcerative oral mucositis (WHO Grade ≥2) [ Time Frame: 11 weeks ]
Duration of ulcerative oral mucositis (WHO Grade ≥2)
Exploratory: Total number of days of ulcerative oral mucositis (WHO Grade ≥2) [ Time Frame: 11 weeks ]
Total number of days (per subject) of ulcerative oral mucositis (WHO Grade ≥2)
Exploratory: Area under the oral mucositis-severity versus time curves [ Time Frame: 11 weeks ]
Area under the oral mucositis-severity versus time curves
Exploratory: Incidence of Mouth and Throat Soreness [ Time Frame: 11 weeks ]
Mouth and throat soreness will be assessed daily using Oral Mucositis Daily Questionnaire (OMDQ) Question #2
Exploratory: Quality of Life (QOL) Assessment [ Time Frame: 11 weeks ]
Quality of Life assessed weekly (FACT-H&N)
Exploratory: Incidence of Analgesic Concumption [ Time Frame: 11 weeks ]
Analgesic consumption for pain due to OM
Exploratory: Incidence of Gastrostomy tube (G-tube) use [ Time Frame: 11 weeks ]
Use of gastrostomy tube (G-tube) for nutritional support due to OM
Exploratory: Incidence of Unplanned Office Visits [ Time Frame: 11 weeks ]
Number of Unplanned Office visits, emergency department visits, and hospital admissions due to OM
Exploratory: Incidence of Unplanned Delays in Chemotherapy and/or RT Schedule [ Time Frame: 11 weeks ]
Incidence of Unplanned Delays in Chemotherapy and/or RT Schedule due to OM
The patent PR today and the fact Leo told Cox he has met with congressional reps to discuss cost treatments of OM points to------BP making sure all is set!!! IMO.
I think we see B data in a few different releases this month and maybe next month. I also think we get Kevetrin data this month. And then we will get P topline in Febish.
This is always sick to watch because we see so many foolish things to help one gain and a company who is undoubtedly trying to save lives is hurt in the process.
However, all the nonsense is just that. Leo and Art are entertaining offers as we speak. The real world and science will prevail and this will rise as BP understands the market potential and will pay a nice price when full data is released.
“Given the positive topline data, the Company is compelled to aggressively seek a development path that will most efficiently bring Brilacidin-OM to patients in need,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We intend to work diligently with the FDA and other health authorities, on a worldwide basis, and ideally in collaboration with interested potential partners, to achieve this goal. We have a potential “game changer” asset with Brilacidin-OM, able to make a big impact on a cancer patient’s well-being, and we are in the privileged position of planning wholeheartedly for the next stage of development as we strive to be the first to fill a wide void in oncology as quickly as possible.”
“We are looking at a global product opportunity with OM that is extremely attractive and intellectual property protection is critical. With no approved drugs for our initial target indication in preventing OM in HNC, the first company to commercialize a safe and effective drug would undoubtedly command a significant portion of the market, which is estimated to be at least $1 billion worldwide,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
We will get more details and data in upcoming weeks. The results from yesterday do in fact warrant a partnership and all hands on deck to get OM to approval. IMO.
What you just posted is wrong. It's 35ish percent got OM! So the prevention is 60 PLUS percent.
Brilacidin prevents OM in over 60% of patients.
A simple swish and spit giving a cancer patient 60% chance of NOT getting severe OM is good. The numbers may be better when we get more data. This was just topline
Protect and expand the IP! We will be the first preventive drug for OM imo!!!!
Awesome!!!! Thanks
That's the reality. We will shed these little people one day. Good data and I am hopeful our partner can tweak the formulation to make it even better
Welcome back! Good data today. Actually it's the best data out there for any phase 2 OM trial.
Partner in 3-2-1! Soon and I expect you will disappear.
Good write up! Thanks. I was telling my friends who are in this....it would be amazing for Leo to release results and then release partner news 2-3 hours later to screw all the traders and shorts.
Good data for OM, and I expect BT designation with a 60% plus prevention line.
Watch and see the cancer types and maybe OM was 100% preventative in some.
Exactly! Still batting 1000!!!! IPIX has never failed. ;)
They will now dice up types of cancer, duration etc....a lot of data to chew. On to phase 3 baby
Leo will put a nice milestone for Breakthrough in the deal ;). Another catalyst maybe? This stock is about to make huge gains and the IPIX story will be very exciting in the upcoming years imo.
BOM soon. Who cares when. All that matters is the data. Billion market. Sleep well all
Boom! Let's go OM results
How about an after hours result PR;). With a Monday partner PR? That would confuse the chartists
Plus....iPIX is done with phase 2. While the only other competitor out there with the same preventative primary outcome will start dosing their phase 2 next year.
We are a couple years ahead and they are just starting a phase 2 on a hunch the drug should work in OM from the MOA on a separate indication.
Some people may enjoy the security of after. There was a poster who put it brilliantly a couple days back......this is like the gold rush and the B-OM trial and results is finding your first nugget! At that point what do you do? Answer you go all in and set up camp, build a shelter and get to work for many months and years ahead.
B-OM IF RESULTS ARE GOOD (not even great) will move IPIX to partnerships, possibly chained with UP/UC and more partnerships for IBD indications since the MOA relates...uplist....etc!
If things go well here now for OM, imagine what the SP could be by the time we get to Prurisol data in a couple months!!!!!
IMO. Gonna be a fun ride $$$$$
Good read. OM - an untapped market. Dr. Bertolino from Revance moved to one of the companies on the list.
https://www.baystreet.ca/articles/stockstowatch/34608/A-Billion-Dollar-Market-Just-Waiting-for-a-New-Oral-Mucositis-Drug-Five-Companies-That-Want-It
We just need good and hopefully great data to make them squirm and move quickly. An untapped market is something like a unicorn in the biotech. It's hard to find. IMO.
IMO. Ready to roll
Thank you Sir!!! Was out most of day. But it looked great! Sliced thru that 1.08......the wall that many were scared of. Lol. And then peeps took profits and we stick an 11% gain on the uptrend into Thirsty Thursday!
Great day! Great volume!
What is the final price/volume? Please
I think we see 100K more buys coming by end of day. Max if you need to sell any
Great volume and great day!!!! Something may happen tomorriw
Wow. Those million short are probably trying to cover